Compare CHMI & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | ANVS |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.5M | 69.1M |
| IPO Year | N/A | 2019 |
| Metric | CHMI | ANVS |
|---|---|---|
| Price | $2.38 | $1.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $13.50 |
| AVG Volume (30 Days) | 181.5K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 15.09% | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $61.13 | N/A |
| P/E Ratio | $139.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $1.54 |
| 52 Week High | $3.04 | $5.50 |
| Indicator | CHMI | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 36.75 | 43.64 |
| Support Level | $2.25 | $1.79 |
| Resistance Level | $2.46 | $2.57 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 12.00 | 24.29 |
Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.